Morgan Stanley
NVCT icon

Morgan Stanley’s Nuvectis Pharma NVCT Stock Holding History

Morgan Stanley’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$344K Sell
18,721
-3,847
-17% -$43.1K ﹤0.01% 5716
2026
Q1 		$174K Sell
22,568
-5,443
-19% -$46.6K ﹤0.01% 5929
2025
Q4 		$211K Buy
28,011
+9,494
+51% +$61.9K ﹤0.01% 5910
2025
Q3 		$111K Sell
18,517
-6,176
-25% -$42.5K ﹤0.01% 6107
2025
Q2 		$184K Buy
24,693
+17,716
+254% +$161K ﹤0.01% 5887
2025
Q1 		$68.2K Buy
6,977
+4,658
+201% +$33.5K ﹤0.01% 6167
2024
Q4 		$12.5K Sell
2,319
-29
-1% -$182 ﹤0.01% 6725
2024
Q3 		$14.8K Sell
2,348
-7,850
-77% -$51.7K ﹤0.01% 6601
2024
Q2 		$64.6K Sell
10,198
-30,993
-75% -$211K ﹤0.01% 6099
2024
Q1 		$338K Buy
41,191
+18,276
+80% +$155K ﹤0.01% 5506
2023
Q4 		$191K Buy
22,915
+19,436
+559% +$173K ﹤0.01% 5720
2023
Q3 		$44.8K Sell
3,479
-1,624
-32% -$23.5K ﹤0.01% 6210
2023
Q2 		$81.5K Buy
5,103
+1,988
+64% +$31.7K ﹤0.01% 6034
2023
Q1 		$40.8K Buy
3,115
+2,814
+935% +$28.5K ﹤0.01% 6354
2022
Q4 		$2.26K Buy
301
+100
+50% +$716 ﹤0.01% 7341
2022
Q3 		$1K Buy
201
+1
+0.5% +$9 ﹤0.01% 7584
2022
Q2 		$2K Buy
+200
New +$2.47K ﹤0.01% 7601

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Morgan Stanley's NVCT Position: Q2 2026 in Review

Morgan Stanley reduced its Nuvectis Pharma (NVCT) stake by 17% in Q2 2026, selling an estimated $43.1K and leaving 18,721 shares worth $344K. The position accounts for ﹤0.01% of the portfolio, ranked #5716.

Morgan Stanley first reported a position in NVCT in Q2 2022 and has held it in 17 quarters since. 82 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Morgan Stanley held 18,721 shares of Nuvectis Pharma worth $344K as of Q2 2026.
  • Morgan Stanley sold 3,847 Nuvectis Pharma shares in Q2 2026, an estimated $43.1K.
  • Nuvectis Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5716 holding.
  • Morgan Stanley first reported a position in Nuvectis Pharma in Q2 2022 and has held it in 17 quarters since.
  • 82 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.